Fig 1: CXCR3-A-modified CAR T cells show enhanced migration and efficacy against DIPG across multiple T cell donors in response to CXCR3 ligands.a Percentage of CAR T cells that migrated from insert wells to bottom wells with vehicle, 300 ng/mL CXCL9, 100 ng/mL CXCL10, or 300 ng/mL CXCL11 after 2 hours. b Relative cell viability of PBT-29FH cells after co-cultured with migrated CAR T cells for 24 hours. CAR T cells were seeded on insert wells to migrate to bottom wells with vehicle, 300 ng/mL CXCL9, 100 ng/mL CXCL10, or 300 ng/mL CXCL11 for 2 hours before removal of the insert wells. c Concentrations of IL-2, IFN-γ, and TNF by ELISA in cultures from (b) after 24 hours. d Relative cell viability of PBT-29FH cells after directly co-cultured with CAR T cells at E:T of 1:1 in the presence of vehicle, 300 ng/mL CXCL9, 100 ng/mL CXCL10, or 300 ng/mL CXCL11 for 24 hours. e Concentrations of IL-2, IFN-γ, and TNF by ELISA in cultures from (d) after 24 hours. Cell viability was normalized to the vehicle control without T cells in (b, d). p values were determined by randomized block (matching the data for each donor) two-way ANOVA with Sidak’s multiple comparisons test (a–e, n = 3 different T cell donors). Results are presented as means ± SD. ns, not significant. Source data are provided as a Source Data file.